Pharmacological Management of Heart Failure

Correct Answer

C — Lisinopril

Rationale

Lisinopril is an angiotensin-converting enzyme inhibitor, a drug class that blocks the enzyme responsible for converting angiotensin I to angiotensin II. Losartan is an angiotensin receptor blocker — it acts one step downstream by blocking the receptor that angiotensin II acts on, rather than preventing its formation. Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor — a combination class that pairs angiotensin receptor blockade with neprilysin inhibition. Aliskiren is a direct renin inhibitor, acting at the first step of the renin-angiotensin-aldosterone system cascade. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

A — Losartan

Rationale

Losartan is an angiotensin receptor blocker, a drug class that blocks the receptor that angiotensin II acts on. Lisinopril is an angiotensin-converting enzyme inhibitor — it prevents the formation of angiotensin II rather than blocking its receptor. Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor — a separate combined class that includes an angiotensin receptor blocker component (valsartan) paired with a neprilysin inhibitor (sacubitril). Spironolactone is a mineralocorticoid receptor antagonist that acts further downstream in the renin-angiotensin-aldosterone system cascade, blocking aldosterone's receptor rather than angiotensin II's receptor.

Correct Answer

D — Enalapril

Rationale

Enalapril is an angiotensin-converting enzyme inhibitor, in the same class as lisinopril and ramipril. Candesartan is an angiotensin receptor blocker. Carvedilol is a non-selective beta-adrenergic receptor antagonist and one of the three beta-blockers with proven mortality benefit in heart failure with reduced ejection fraction. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

B — Candesartan

Rationale

Candesartan is an angiotensin receptor blocker, in the same class as losartan and valsartan. Angiotensin receptor blockers block the receptor that angiotensin II acts on without affecting the enzyme that degrades bradykinin, which is the key distinction from angiotensin-converting enzyme inhibitors. Lisinopril is an angiotensin-converting enzyme inhibitor. Aliskiren is a direct renin inhibitor. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

C — Valsartan

Rationale

Valsartan is an angiotensin receptor blocker. It is also the angiotensin receptor blocker component of the combination drug sacubitril/valsartan, which pairs valsartan with sacubitril (a neprilysin inhibitor) to form the angiotensin receptor-neprilysin inhibitor class. When valsartan is used alone, it is classified as an angiotensin receptor blocker. Enalapril is an angiotensin-converting enzyme inhibitor. Spironolactone is a mineralocorticoid receptor antagonist. Sacubitril alone is a neprilysin inhibitor — it is not an angiotensin receptor blocker and is not used as a standalone drug in heart failure.

Correct Answer

A — Sacubitril/valsartan

Rationale

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, is now the preferred renin-angiotensin-aldosterone system blocker in heart failure with reduced ejection fraction for patients who can tolerate it, having demonstrated a greater reduction in mortality and hospitalization than an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker alone. Aliskiren is a direct renin inhibitor that is not a guideline-recommended agent in heart failure. Spironolactone is a mineralocorticoid receptor antagonist — it is one of the four guideline-directed therapy pillars but acts on aldosterone, not angiotensin II. Hydralazine is a direct arterial vasodilator used as an alternative when renin-angiotensin-aldosterone system blockers cannot be tolerated.

Correct Answer

D — Lisinopril blocks the enzyme that normally degrades bradykinin, causing bradykinin to accumulate in the airway

Rationale

Angiotensin-converting enzyme has two substrates: it converts angiotensin I to angiotensin II, and it also degrades bradykinin, a peptide that promotes vasodilation and can irritate airway tissue. When lisinopril blocks this enzyme, bradykinin accumulates. In the airway, elevated bradykinin triggers a persistent dry cough — the most common reason patients are switched from an angiotensin-converting enzyme inhibitor to an angiotensin receptor blocker. This adverse effect is class-wide: all angiotensin-converting enzyme inhibitors raise bradykinin and carry this risk. Option A reverses the pharmacology — it is the blockade of angiotensin II signaling, not stimulation, that is the therapeutic goal. Option B describes the mechanism of non-steroidal anti-inflammatory drug-related gastrointestinal effects, not angiotensin-converting enzyme inhibitor cough. Option C describes the mechanism of non-selective beta-blockers, not angiotensin-converting enzyme inhibitors.

Correct Answer

B — Angiotensin receptor blockers block the angiotensin II receptor without inhibiting the enzyme that degrades bradykinin, so bradykinin levels remain normal

Rationale

Angiotensin-converting enzyme inhibitors cause cough because they block the enzyme that converts angiotensin I to angiotensin II — and that same enzyme also degrades bradykinin. When the enzyme is blocked, bradykinin accumulates and irritates the airway. Angiotensin receptor blockers work one step downstream: they block the receptor that angiotensin II acts on, achieving similar clinical benefits, but they do not touch the enzyme that degrades bradykinin. Bradykinin metabolism is therefore unaffected, and bradykinin levels remain normal. This is why switching from an angiotensin-converting enzyme inhibitor to an angiotensin receptor blocker reliably eliminates the cough. Option A is a mischaracterization — angiotensin receptor blockers do not lower angiotensin II levels; they block its receptor while angiotensin II continues to be produced. Option C misidentifies the mechanism. Option D describes a pharmacological action that angiotensin receptor blockers do not have.

Correct Answer

A — Angioedema from angiotensin-converting enzyme inhibitors is caused by bradykinin accumulation, and re-exposure to any drug in the class will again block bradykinin degradation, risking recurrence

Rationale

Angioedema is a rare but potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Like cough, it is caused by the accumulation of bradykinin when the enzyme responsible for its degradation is blocked. Bradykinin causes increased vascular permeability in the submucosa of the face, lips, tongue, and airway, producing the rapid swelling that defines angioedema. Because the mechanism is pharmacological — intrinsic to the drug class's blockade of bradykinin degradation — any angiotensin-converting enzyme inhibitor will carry the same risk in a patient who has experienced this reaction. Prior angioedema is therefore an absolute contraindication to the entire class. Patients who need renin-angiotensin-aldosterone system blockade should be switched to an angiotensin receptor blocker, which does not affect bradykinin metabolism. Option B reverses the mechanism — it is bradykinin elevation, not angiotensin II excess, that causes angioedema. Options C and D describe mechanisms not associated with angiotensin-converting enzyme inhibitor angioedema.

Correct Answer

C — By reducing angiotensin II activity, these drugs lower aldosterone levels, and aldosterone normally drives potassium excretion by the kidney

Rationale

Angiotensin II normally stimulates the adrenal gland to release aldosterone. Aldosterone acts in the kidney's collecting duct to promote sodium reabsorption and potassium excretion. When angiotensin-converting enzyme inhibitors or angiotensin receptor blockers block angiotensin II activity, aldosterone levels fall. With less aldosterone signaling, the kidney excretes less potassium, and serum potassium rises. This risk is higher in patients with chronic kidney disease (who already have reduced potassium excretion) or in those also taking other potassium-sparing drugs such as mineralocorticoid receptor antagonists. Option A describes a mechanism that does not apply to renin-angiotensin-aldosterone system blockers. Option B misidentifies bradykinin's role in this context. Option D describes the mechanism of loop diuretics such as furosemide, which increase potassium excretion rather than reduce it.

Correct Answer

D — Angiotensin II normally constricts the efferent arteriole to maintain filtration pressure; blocking it dilates the efferent arteriole and modestly reduces the glomerular filtration rate, reflecting the drug working as intended

Rationale

Within the kidney, angiotensin II preferentially constricts the efferent arteriole (the vessel leaving the glomerulus), which raises the pressure inside the glomerulus and maintains the glomerular filtration rate. When an angiotensin-converting enzyme inhibitor reduces angiotensin II, the efferent arteriole dilates, glomerular pressure falls slightly, and the glomerular filtration rate decreases modestly. This causes a small rise in serum creatinine. Because this reflects the intended hemodynamic effect of the drug on kidney blood flow — not acute kidney injury from toxicity — a mild rise is expected and tolerated. The module states explicitly that a mild creatinine rise is not by itself a reason to stop the medication. A large or rapidly progressive rise in creatinine, however, would warrant investigation, particularly for bilateral renal artery stenosis. Options A, B, and C each describe mechanisms that do not account for this expected finding.

Correct Answer

B — Neprilysin also degrades angiotensin II, so inhibiting neprilysin alone would raise angiotensin II levels, working against the goal of treatment

Rationale

Neprilysin degrades multiple peptide substrates, including natriuretic peptides — which is the desired effect to amplify — but also angiotensin II itself. When neprilysin is inhibited, angiotensin II degrades more slowly and its levels rise. In heart failure, elevated angiotensin II is harmful: it raises afterload, promotes fibrosis, and drives disease progression. Inhibiting neprilysin alone would therefore simultaneously produce a beneficial effect (more natriuretic peptides) and a harmful one (more angiotensin II). Combining sacubitril with valsartan, an angiotensin receptor blocker, solves this: valsartan blocks the angiotensin II receptor so that regardless of how much angiotensin II is produced, its harmful signaling is prevented. This pharmacological logic is what makes the combination design necessary, not merely conventional. Option A mischaracterizes the role of bradykinin in this context. Option C reverses the effect — neprilysin inhibition raises, not suppresses, natriuretic peptides. Option D incorrectly attributes angiotensin-converting enzyme inhibitor activity to sacubitril.

Correct Answer

A — These drugs are teratogenic because angiotensin II is required for normal fetal kidney development, and blocking it causes fetal renal injury and related complications

Rationale

Angiotensin II plays an essential role in fetal kidney development. Blocking the renin-angiotensin-aldosterone system during pregnancy — with either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker — disrupts this developmental process and can cause fetal renal tubular dysplasia, oligohydramnios (reduced amniotic fluid from decreased fetal urine output), skull ossification defects, and neonatal renal failure. These effects are seen with both drug classes and occur across all three trimesters, making renin-angiotensin-aldosterone system blockers absolutely contraindicated throughout pregnancy. Women of childbearing potential who are started on these drugs should be counseled about this risk. Options B, C, and D each describe mechanisms not responsible for the teratogenic risk of renin-angiotensin-aldosterone system blockers.

Correct Answer

C — Both sacubitril and angiotensin-converting enzyme inhibitors reduce bradykinin degradation through separate pathways, and combining them causes excessive bradykinin accumulation with a high risk of angioedema

Rationale

Bradykinin is normally degraded by two separate enzymes. Angiotensin-converting enzyme is one route; neprilysin is another. Angiotensin-converting enzyme inhibitors block the first route, raising bradykinin modestly — enough to cause cough in many patients and angioedema in a few. Sacubitril inhibits neprilysin, blocking the second route. When the two drugs are combined, both routes of bradykinin degradation are simultaneously blocked, causing bradykinin to accumulate to levels far higher than either drug alone would produce. This dramatically increases the risk of angioedema, which can be life-threatening. For this reason, patients must stop an angiotensin-converting enzyme inhibitor at least 36 hours before starting sacubitril/valsartan. Option A mischaracterizes the mechanism — valsartan blocks the angiotensin II receptor, not the enzyme, and this is a different concern from the bradykinin interaction. Options B and D describe mechanisms that do not apply to this drug combination.

Correct Answer

B — Lisinopril blocks the enzyme that normally degrades bradykinin, causing bradykinin to accumulate in the airway and trigger a cough reflex

Rationale

Angiotensin-converting enzyme degrades both angiotensin I (converting it to angiotensin II) and bradykinin. When lisinopril blocks this enzyme, bradykinin accumulates throughout the body, including in the airways, where it stimulates cough receptors and produces a dry, persistent cough. This is the most common reason patients are switched from an angiotensin-converting enzyme inhibitor to an angiotensin receptor blocker. Angiotensin receptor blockers block the angiotensin II receptor without affecting the enzyme that degrades bradykinin, so bradykinin levels remain normal and cough does not occur. The cough in this patient resolved when he was switched to losartan, which is the expected outcome. Options A, C, and D each describe mechanisms that do not account for angiotensin-converting enzyme inhibitor cough.

Correct Answer

D — Sacubitril inhibits neprilysin, one of the enzymes that degrades bradykinin, so patients who experienced bradykinin-mediated angioedema on an angiotensin-converting enzyme inhibitor remain at risk with sacubitril/valsartan

Rationale

Angioedema from angiotensin-converting enzyme inhibitors is caused by bradykinin accumulation — the result of blocking one of the enzymes that normally degrades it. Sacubitril inhibits neprilysin, a different enzyme that also degrades bradykinin. A patient whose bradykinin-mediated angioedema pathway has been sensitized or who is susceptible to the effects of bradykinin excess therefore remains at risk when neprilysin is inhibited by sacubitril. The module states explicitly that a history of angioedema with an angiotensin-converting enzyme inhibitor is a contraindication to sacubitril/valsartan for this reason. Patients in this situation who still need renin-angiotensin-aldosterone system blockade can use an angiotensin receptor blocker alone, which does not affect bradykinin metabolism. Options A, B, and C each describe mechanisms that do not account for this contraindication.

Correct Answer

A — Lisinopril reduces angiotensin II activity, which lowers aldosterone levels; with less aldosterone signaling, the kidney excretes less potassium and serum levels rise

Rationale

Angiotensin II normally stimulates the adrenal gland to release aldosterone. Aldosterone acts in the kidney's collecting duct to promote sodium reabsorption and, in exchange, drive potassium excretion into the urine. When lisinopril blocks the formation of angiotensin II, aldosterone levels fall, and the kidney excretes less potassium. The result is a rise in serum potassium — hyperkalemia. This risk is heightened in patients with chronic kidney disease, who already have impaired potassium handling, which explains why this patient's potassium rose more than might be expected. Monitoring potassium and kidney function after starting angiotensin-converting enzyme inhibitors is standard practice. Options B, C, and D each describe mechanisms that do not account for the expected potassium rise with angiotensin-converting enzyme inhibitors.

Correct Answer

C — Sacubitril/valsartan simultaneously blocks the renin-angiotensin-aldosterone system and amplifies protective natriuretic peptides, producing more complete neurohormonal benefit than an angiotensin-converting enzyme inhibitor alone

Rationale

Angiotensin-converting enzyme inhibitors like enalapril work by blocking the formation of angiotensin II, reducing its harmful effects on the vasculature and heart. Sacubitril/valsartan does this and more: the valsartan component blocks the angiotensin II receptor (providing similar renin-angiotensin-aldosterone system blockade to enalapril), while the sacubitril component inhibits neprilysin, slowing the breakdown of natriuretic peptides and amplifying their beneficial effects of vasodilation, sodium excretion, and anti-fibrotic signaling. This dual action — blocking a harmful neurohormonal system while simultaneously amplifying a protective one — produces a more complete neurohormonal effect and has demonstrated greater reductions in mortality and hospitalization than an angiotensin-converting enzyme inhibitor alone. Option A focuses only on blood pressure; blood pressure reduction is a secondary benefit, not the mechanistic basis for preferring sacubitril/valsartan. Option B overstates the benefit — sacubitril/valsartan carries its own risks of hypotension and hyperkalemia. Option D is a mischaracterization — sacubitril/valsartan does not directly increase contractility.